Ac­celeron res­ur­rects block­buster hopes for so­tater­cept with pos­i­tive PhII — and shares rock­et up

Ac­celeron $XL­RN says that its first ma­jor tri­al read­out of 2020 is a suc­cess.

In a Phase II study of 106 pa­tients with pul­monary ar­te­r­i­al hy­per­ten­sion (PAH), Ac­celeron’s ex­per­i­men­tal drug so­tater­cept hit its pri­ma­ry end­point: a sig­nif­i­cant re­duc­tion in pul­monary vas­cu­lar re­sis­tance. The drug al­so met three dif­fer­ent sec­ondary end­points, in­clud­ing the 6-minute walk­ing test.

“We’re thrilled to re­port such pos­i­tive topline re­sults from the PUL­SAR tri­al,” Ac­celeron CEO Habib Dable said in a state­ment. The com­pa­ny said in a con­fer­ence call they plan on dis­cussing a Phase III tri­al de­sign with reg­u­la­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER